No full text
Article (Scientific journals)
Hydroxyuree et infection par le VIH
Nkoghe, D.; Kola, L.; Leonard, Philippe et al.
2000In Revue Médicale de Liège, 55 (7), p. 721-4
Peer reviewed
 

Files


Full Text
No document available.

Send to



Details



Abstract :
[en] Hydroxyurea is an anticancerous product, used recently in the treatment of HIV-1 infection thanks to its inhibitory action in viral replication, potentialization of the nucleosides activity (particularly ddI or didanosine) and its cytostatic properties on CD4 and CD8 lymphocytes. Many studies showed its efficiency, as further drug, in initial regimen of a tritherapy (containing ddI) and salvage therapy. The dosage of 500 mg bid seems tolerated well by adults, and 20 mg/kg by children. Long-term tolerance remains unknown. With ddI, it could be proposed in developing countries.
Disciplines :
Immunology & infectious disease
Author, co-author :
Nkoghe, D.
Kola, L.
Leonard, Philippe ;  Centre Hospitalier Universitaire de Liège - CHU > Maladies infectieuses et médecine interne générale
Demonty, Jean ;  Centre Hospitalier Universitaire de Liège - CHU > Maladies infectieuses et médecine interne générale
Moutschen, Michel  ;  Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Transplantation
Language :
French
Title :
Hydroxyuree et infection par le VIH
Alternative titles :
[en] Hydroxyurea and Hiv Infection
Publication date :
July 2000
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
55
Issue :
7
Pages :
721-4
Peer reviewed :
Peer reviewed
Available on ORBi :
since 28 April 2013

Statistics


Number of views
48 (2 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
1
Scopus citations®
without self-citations
1

Bibliography


Similar publications



Contact ORBi